Angeion v. Cardiac Pacemakers, Inc.
This article was originally published in The Gray Sheet
Executive Summary
Magistrate judge recommends in a Report and Recommendation that a Minneapolis district court judge grant Angeion's motions for summary judgment and deny the Guidant subsidiary's counter motions for summary judgment of non-infringement that its Mini I and II automatic implantable cardioverter defibrillators infringe certain claims of three Angeion patents related to smaller size, smaller capacitance and "Hot Can-like" features of Angeion devices. The judge also recommends that a claim related to a fourth Angeion patent be dismissed. Angeion and CPI have up to twenty days to file responses to the report, after which time the district court judge will make a final ruling. A jury will consider sometime this fall claims of validity and enforceability of the patents, as well as any possible damages or willful infringement...
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.